Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Our mission at Praxis Precision Medicines, is to drive the development of transformative medicines for patients with rare and complex diseases.

Praxis Precision Medicines’ vision is to become a leader in the discovery and development of novel therapeutics targeting genetically defined diseases, while supporting a culture of transparency, collaboration, and diversity.

Praxis Precision Medicines has received several awards, including the Sanofi Top 25 Global Open Innovation Partner Award in 2019, Endpoints News’ 30 Hottest Companies in Biopharma Startups in 2019, and U.S. Department of Defense-U.S. Army Small Business Innovation Research award in 2018.